We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer (BAYRY) Moves 17.0% Higher: Will This Strength Last?
Read MoreHide Full Article
Bayer Aktiengesellschaft (BAYRY - Free Report) shares rallied 17% in the last trading session to close at $13.16. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.2% gain over the past four weeks.
Shares of Bayer AG surged after the U.S. Supreme Court issued a landmark 7-2 ruling in the Durnell Roundup case, confirming that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) expressly preempts state-law failure-to-warn claims when the U.S. Environmental Protection Agency (EPA) has made a definitive safety determination. The latest decision by the Supreme Court, which garnered broad support across the Court's ideological spectrum, is expected to significantly curb Roundup related litigation costs. The ruling reinforces the EPA's authority over pesticide labeling and safety determinations, affirming that companies’ complying with federally approved labeling requirements cannot be held liable under a patchwork of state tort laws.
This company is expected to post quarterly earnings of $0.23 per share in its upcoming report, which represents a year-over-year change of -34.3%. Revenues are expected to be $12.32 billion, up 1.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Bayer, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on BAYRY going forward to see if this recent jump can turn into more strength down the road.
Bayer belongs to the Zacks Large Cap Pharmaceuticals industry. Another stock from the same industry, Innoviva (INVA - Free Report) , closed the last trading session 1.2% lower at $23.35. Over the past month, INVA has returned 6.8%.
For Innoviva, the consensus EPS estimate for the upcoming report has changed +9.8% over the past month to $0.56. This represents a change of -27.3% from what the company reported a year ago. Innoviva currently has a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Bayer (BAYRY) Moves 17.0% Higher: Will This Strength Last?
Bayer Aktiengesellschaft (BAYRY - Free Report) shares rallied 17% in the last trading session to close at $13.16. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.2% gain over the past four weeks.
Shares of Bayer AG surged after the U.S. Supreme Court issued a landmark 7-2 ruling in the Durnell Roundup case, confirming that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) expressly preempts state-law failure-to-warn claims when the U.S. Environmental Protection Agency (EPA) has made a definitive safety determination. The latest decision by the Supreme Court, which garnered broad support across the Court's ideological spectrum, is expected to significantly curb Roundup related litigation costs. The ruling reinforces the EPA's authority over pesticide labeling and safety determinations, affirming that companies’ complying with federally approved labeling requirements cannot be held liable under a patchwork of state tort laws.
This company is expected to post quarterly earnings of $0.23 per share in its upcoming report, which represents a year-over-year change of -34.3%. Revenues are expected to be $12.32 billion, up 1.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Bayer, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on BAYRY going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Bayer belongs to the Zacks Large Cap Pharmaceuticals industry. Another stock from the same industry, Innoviva (INVA - Free Report) , closed the last trading session 1.2% lower at $23.35. Over the past month, INVA has returned 6.8%.
For Innoviva, the consensus EPS estimate for the upcoming report has changed +9.8% over the past month to $0.56. This represents a change of -27.3% from what the company reported a year ago. Innoviva currently has a Zacks Rank of #3 (Hold).